Zepbound® (tirzepatide) 7.5 mg/0.5 mL Vial

Product Description: Zepbound® (tirzepatide) 7.5 mg/0.5 mL Vial

Zepbound® (tirzepatide) is a once-weekly injectable prescription medication indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. The 7.5 mg/0.5 mL dosage is a therapeutic titration step, typically prescribed after a patient has completed at least four weeks at the 5 mg dosage level and requires further optimization of weight loss results.

Product Specifications

• Dosage Strength: 7.5 mg per 0.5 mL.

• Presentation: Single-dose vial (Requires the use of sterile, single-use syringes and needles for administration).

• Indication: Chronic weight management in adults with an initial BMI of $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) with at least one weight-related comorbid condition.

• Administration: Subcutaneous injection once weekly in the abdomen, thigh, or upper arm.

• Mechanism of Action: Acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By stimulating these receptors, it enhances insulin secretion, slows gastric emptying, and increases satiety to reduce overall caloric intake.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

Tirzepatide has been shown to cause thyroid C-cell tumors in rodents. It is unknown if Zepbound causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Clinical Considerations

• Dose Escalation: This dosage is designed for patients who have demonstrated tolerance to the 5 mg dose. Clinical providers should assess the patient’s gastrointestinal tolerance before and during this escalation, as side effects (e.g., nausea, vomiting, diarrhea) may intensify with higher doses.

• Contraindications: History of MTC/MEN 2; known serious hypersensitivity to tirzepatide or any product components.

• Preparation: As this presentation is a vial, users must be proficient in sterile syringe techniques to ensure the precise volume of 0.5 mL is drawn and administered.

• Hypoglycemia: Monitor patients closely, particularly those on concurrent insulin or insulin secretagogues, as the risk of hypoglycemia may increase with dose escalation.

Storage and Handling

• Refrigeration: Store in the refrigerator at 36°F to 46°F (2°C to 8°C).

• Room Temperature: If necessary, the vial may be stored at room temperature (up to 86°F or 30°C) for a maximum of 21 days.

• Light Protection: Always store the vial in the original carton to protect the medication from light. Do not freeze. Inspect the solution before use; it should be a clear, colorless to slightly yellow liquid, free of visible particles.

Disclaimer: This information is provided for professional reference only and does not constitute medical advice, diagnosis, or treatment. Always refer to the official FDA-approved Prescribing Information, Medication Guide, and Instructions for Use for comprehensive clinical guidance.